Home » Newsletters » BioWorld Science

BioWorld Science

May 9, 2022

View Archived Issues

Discovery of GB-1101, selective oral HDAC6 inhibitor with potent antitumor activity in vivo

Gannex Pharma presents new FXR agonists

Novel biomarkers for identifying progression of diabetic retinopathy

XuanZhu Pharma divulges AhR antagonists

Gasherbrum Bio identifies new GLP-1 receptor agonists

New PADI4 inhibitors disclosed by Helios-Huaming BioPharma

Jiangsu Simcere Pharmaceutical synthesizes new Mat2A inhibitors

Celgene ERK/NLK inhibitor CC-91516 shows activity against BRAF and CTNNB1 mutant tumors

Targeting NR2E3 is a potential approach to avoid photoreceptor degeneration in retinitis pigmentosa

Proline links gut microbiome to depression

Novel variant in the DHX38 gene tied to congenital dyserythropoietic anemia with ring sideroblasts

Studies identify genetic risk factors for hyperemesis gravidarum and recurrence

AGEN-1571 reverses ILT-2-mediated immunosuppression to activate antitumor immunity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.